Literature DB >> 29248459

Discrete Pools of Oligomeric Amyloid-β Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis.

Angie C A Chiang1, Stephanie W Fowler1, Rohit Reddy2, Olga Pletnikova3, Juan C Troncoso3, Mathew A Sherman4, Sylvain E Lesne4, Joanna L Jankowsky5.   

Abstract

Despite increasing appreciation that oligomeric amyloid-β (Aβ) may contribute to cognitive decline of Alzheimer disease, defining the most critical forms has been thwarted by the changeable nature of these aggregates and the varying methods used for detection. Herein, using a broad approach, we quantified Aβ oligomers during the evolution of cognitive deficits in an aggressive model of Aβ amyloidosis. Amyloid precursor protein/tetracycline transactivator mice underwent behavioral testing at 3, 6, 9, and 12 months of age to evaluate spatial learning and memory, followed by histologic assessment of amyloid burden and biochemical characterization of oligomeric Aβ species. Transgenic mice displayed progressive impairments in acquisition and immediate recall of the trained platform location. Biochemical analysis of cortical extracts from behaviorally tested mice revealed distinct age-dependent patterns of accumulation in multiple oligomeric species. Dot blot analysis demonstrated that nonfibrillar Aβ oligomers were highly soluble and extracted into a fraction enriched for extracellular proteins, whereas prefibrillar species required high-detergent conditions to retrieve, consistent with membrane localization. Low-detergent extracts tested by 82E1 enzyme-linked immunosorbent assay confirmed the presence of bona fide Aβ oligomers, whereas immunoprecipitation-Western blotting using high-detergent extracts revealed a variety of SDS-stable low-n species. These findings show that different Aβ oligomers vary in solubility, consistent with distinct localization, and identify nonfibrillar Aβ oligomer-positive aggregates as tracking most closely with cognitive decline in this model.
Copyright © 2018 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29248459      PMCID: PMC5840490          DOI: 10.1016/j.ajpath.2017.11.011

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  85 in total

1.  Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.

Authors:  R D Terry; E Masliah; D P Salmon; N Butters; R DeTeresa; R Hill; L A Hansen; R Katzman
Journal:  Ann Neurol       Date:  1991-10       Impact factor: 10.422

2.  Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Authors:  Gaël Chételat; Victor L Villemagne; Kerryn E Pike; Kathryn A Ellis; Pierrick Bourgeat; Gareth Jones; Graeme J O'Keefe; Olivier Salvado; Cassandra Szoeke; Ralph N Martins; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Brain       Date:  2011-02-09       Impact factor: 13.501

3.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

4.  Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo.

Authors:  Igor Klyubin; Dominic M Walsh; Cynthia A Lemere; William K Cullen; Ganesh M Shankar; Vicki Betts; Edward T Spooner; Liying Jiang; Roger Anwyl; Dennis J Selkoe; Michael J Rowan
Journal:  Nat Med       Date:  2005-04-17       Impact factor: 53.440

5.  The effects of aging on N-methyl-D-aspartate receptor subunits in the synaptic membrane and relationships to long-term spatial memory.

Authors:  X Zhao; R Rosenke; D Kronemann; B Brim; S R Das; A W Dunah; K R Magnusson
Journal:  Neuroscience       Date:  2009-05-13       Impact factor: 3.590

Review 6.  Axonopathy and cytoskeletal disruption in degenerative diseases of the central nervous system.

Authors:  James C Vickers; Anna E King; Adele Woodhouse; Matthew T Kirkcaldie; Jerome A Staal; Graeme H McCormack; Catherine A Blizzard; Ruth E J Musgrove; Stanislaw Mitew; Yao Liu; Jyoti A Chuckowree; Olivier Bibari; Tracey C Dickson
Journal:  Brain Res Bull       Date:  2009-08-13       Impact factor: 4.077

Review 7.  Neuroinflammation in Alzheimer's disease.

Authors:  Michael T Heneka; Monica J Carson; Joseph El Khoury; Gary E Landreth; Frederic Brosseron; Douglas L Feinstein; Andreas H Jacobs; Tony Wyss-Coray; Javier Vitorica; Richard M Ransohoff; Karl Herrup; Sally A Frautschy; Bente Finsen; Guy C Brown; Alexei Verkhratsky; Koji Yamanaka; Jari Koistinaho; Eicke Latz; Annett Halle; Gabor C Petzold; Terrence Town; Dave Morgan; Mari L Shinohara; V Hugh Perry; Clive Holmes; Nicolas G Bazan; David J Brooks; Stéphane Hunot; Bertrand Joseph; Nikolaus Deigendesch; Olga Garaschuk; Erik Boddeke; Charles A Dinarello; John C Breitner; Greg M Cole; Douglas T Golenbock; Markus P Kummer
Journal:  Lancet Neurol       Date:  2015-04       Impact factor: 44.182

8.  Biology and pathophysiology of the amyloid precursor protein.

Authors:  Hui Zheng; Edward H Koo
Journal:  Mol Neurodegener       Date:  2011-04-28       Impact factor: 14.195

9.  Cognition, reserve, and amyloid deposition in normal aging.

Authors:  Dorene M Rentz; Joseph J Locascio; John A Becker; Erin K Moran; Elisha Eng; Randy L Buckner; Reisa A Sperling; Keith A Johnson
Journal:  Ann Neurol       Date:  2010-03       Impact factor: 10.422

10.  Genomic mosaicism with increased amyloid precursor protein (APP) gene copy number in single neurons from sporadic Alzheimer's disease brains.

Authors:  Diane M Bushman; Gwendolyn E Kaeser; Benjamin Siddoway; Jurgen W Westra; Richard R Rivera; Stevens K Rehen; Yun C Yung; Jerold Chun
Journal:  Elife       Date:  2015-02-04       Impact factor: 8.140

View more
  6 in total

1.  Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease.

Authors:  Claudia H Huichalaf; Ismael Al-Ramahi; Kyung-Won Park; Stacy D Grunke; Nan Lu; Maria de Haro; Karla El-Zein; Tatiana Gallego-Flores; Alma M Perez; Sung Yun Jung; Juan Botas; Huda Y Zoghbi; Joanna L Jankowsky
Journal:  Hum Mol Genet       Date:  2019-06-15       Impact factor: 6.150

2.  Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice.

Authors:  Angie C A Chiang; Stephanie W Fowler; Ricky R Savjani; Susan G Hilsenbeck; Clare E Wallace; John R Cirrito; Pritam Das; Joanna L Jankowsky
Journal:  J Exp Med       Date:  2018-04-06       Impact factor: 14.307

Review 3.  The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade.

Authors:  Erika N Cline; Maíra Assunção Bicca; Kirsten L Viola; William L Klein
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

4.  Unraveling Early Signs of Navigational Impairment in APPswe/PS1dE9 Mice Using Morris Water Maze.

Authors:  Smitha Karunakaran
Journal:  Front Neurosci       Date:  2020-12-15       Impact factor: 4.677

5.  Ankyrin-R regulates fast-spiking interneuron excitability through perineuronal nets and Kv3.1b K+ channels.

Authors:  Sharon R Stevens; Colleen M Longley; Yuki Ogawa; Lindsay H Teliska; Anithachristy S Arumanayagam; Supna Nair; Juan A Oses-Prieto; Alma L Burlingame; Matthew D Cykowski; Mingshan Xue; Matthew N Rasband
Journal:  Elife       Date:  2021-06-28       Impact factor: 8.140

6.  Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1.

Authors:  Erik C B Johnson; Kaitlyn Ho; Gui-Qiu Yu; Melanie Das; Pascal E Sanchez; Biljana Djukic; Isabel Lopez; Xinxing Yu; Michael Gill; Weiping Zhang; Jeanne T Paz; Jorge J Palop; Lennart Mucke
Journal:  Mol Neurodegener       Date:  2020-09-14       Impact factor: 14.195

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.